Literature DB >> 2894605

The Paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism.

B Ellenbroek1, A R Cools.   

Abstract

Recently we have developed an animal model which could discriminate between classical and atypical neuroleptic drugs: the PAW TEST. This test measures the ability of rats to spontaneously withdraw its force- and hindlimbs. It was found that the ability of drugs to affect the rat's forelimb retraction time was associated with the liability of the drug to induce so-called extra-pyramidal side-effects in man. Likewise the ability of drugs to affect the rat's hindlimb retraction time was associated with the antipsychotic efficacy of the drug. These data open the perspective that the forelimb retraction time (FRT) is an animal analogue of parkinsonian side-effects, and that the hindlimb retraction time (HRT) is an animal analogue of antipsychotic effects In the present series of experiments we further evaluated the validity of these notions by applying the criteria of "pharmacological isomorphism" as proposed by Matthysse (1). Thus HRT had to fulfil the criteria of pharmacological isomorphism for the therapeutic effects of neuroleptics, whereas FRT had to fulfil these criteria for the parkinsonian side-effects. The results of the present study show that both FRT and HRT met these criteria. Thus both classical and atypical neuroleptics were effective in prolonging HRT, whereas only the classical neuroleptics prolonged FRT (criterion 1); the nonneuroleptic phenothiazine promethazine (as well as the narcotic morphine, the muscle relaxant diazepam and the antidepressant desipramine) were ineffective in this respect (criterion 2); the acetylcholinergic antagonist scopolamine blocked the FRT, but not the HRT (criterion 3); chronic neuroleptic treatment reduced the FRT, but not the HRT (criterion 4). In conclusion the paw test, an animal model for testing antipsychotic drugs, was found to fulfil the criteria for "pharmacological isomorphism". Although the exact mechanism underlying the paw test is as yet unknown, the present data improve its validity as an animal model.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894605     DOI: 10.1016/0024-3205(88)90551-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine.

Authors:  A R Cools; E P Prinssen; B A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

2.  Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test.

Authors:  E P Prinssen; B A Ellenbroek; A R Cools
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

3.  Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats.

Authors:  Barbara Bricker; Tanise Jackson; Bernard Boateng; Xue Y Zhu; Seth Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2012-05-12       Impact factor: 3.533

4.  Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis.

Authors:  Mangala Kumari; Premdass Ramdas; Ammu Kutty Radhakrishnan; Methil Kannan Kutty; Nagaraja Haleagrahara
Journal:  Nutrients       Date:  2021-05-10       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.